Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $5.81 in the prior trading day, EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) closed at $5.85, up 0.69%. In other words, the price has increased by $0.69 from its previous closing price. On the day, 0.54 million shares were traded.
Ratios:
Our goal is to gain a better understanding of EYPT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.79 and its Current Ratio is at 7.85. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on January 07, 2025, initiated with a Buy rating and assigned the stock a target price of $33.
On August 28, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $15.Jefferies initiated its Buy rating on August 28, 2024, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 23 ’24 when ANTHONY P. ADAMIS bought 67,100 shares for $10.04 per share.
David R. Guyer bought 36,975 shares of EYPT for $329,817 on Oct 14 ’24. On Aug 20 ’24, another insider, DICICCO WENDY F, who serves as the Director of the company, bought 2,567 shares for $7.79 each. As a result, the insider paid 19,997 and bolstered with 9,967 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 7.18 while its Price-to-Book (P/B) ratio in mrq is 1.35.
Stock Price History:
Over the past 52 weeks, EYPT has reached a high of $13.98, while it has fallen to a 52-week low of $3.91. The 50-Day Moving Average of the stock is -3.91%, while the 200-Day Moving Average is calculated to be -26.49%.
Shares Statistics:
A total of 68.81M shares are outstanding, with a floating share count of 59.69M. Insiders hold about 13.25% of the company’s shares, while institutions hold 98.95% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by 9.0 analysts. The consensus estimate for the next quarter is -$0.72, with high estimates of -$0.55 and low estimates of -$0.83.
Analysts are recommending an EPS of between -$2.05 and -$2.05 for the fiscal current year, implying an average EPS of -$2.05. EPS for the following year is -$2.73, with 9.0 analysts recommending between -$1.54 and -$2.96.
Revenue Estimates
10 analysts predict $6.82M in revenue for the current quarter. It ranges from a high estimate of $11.53M to a low estimate of $6.82M. As of the current estimate, EyePoint Pharmaceuticals Inc’s year-ago sales were $9.48MFor the next quarter, 10 analysts are estimating revenue of $7.85M. There is a high estimate of $11.54M for the next quarter, whereas the lowest estimate is $7.85M.
A total of 12 analysts have provided revenue estimates for EYPT’s current fiscal year. The highest revenue estimate was $46.14M, while the lowest revenue estimate was $29.03M, resulting in an average revenue estimate of $29.03M. In the same quarter a year ago, actual revenue was $43.27MBased on 10 analysts’ estimates, the company’s revenue will be $17.85M in the next fiscal year. The high estimate is $46M and the low estimate is $17.85M.
